Results 91 to 100 of about 414,372 (151)

Pharmacoeconomic evaluation of insulin aspart and glargine in type 1 and 2 diabetes mellitus in Iran. [PDF]

J Diabetes Metab Disord, 2023
Nosrati M, Ahmadi Fariman S, Saiyarsarai P, Nikfar S.   +3 more
europepmc   +1 more source

Retracted: Comparative Analysis of Clinical Effects of Insulin Aspart Combined with Acarbose and Metformin in the Treatment of Diabetes Mellitus. [PDF]

Evid Based Complement Alternat Med, 2023
And Alternative Medicine EC.
europepmc   +1 more source

Fast-Acting Insulin Aspart in Patients with Type 1 Diabetes in Real-World Clinical Practice: A Noninterventional, Retrospective Chart and Database Study. [PDF]

Diabetes Ther, 2023
Lind M, Catrina SB, Ekberg NR, Gerward S, Halasa T, Hellman J, Hess D, Löndahl M, Qvist V, Bolinder J.   +9 more
europepmc   +1 more source

Hybrid Closed-Loop Control with Ultrarapid Lispro Compared with Standard Insulin Aspart and Faster Insulin Aspart: An In Silico Study. [PDF]

J Diabetes Sci Technol, 2023
Lachal S, Tourki Y, Franc S, Huneker E, Charpentier G, Benhamou PY.   +5 more
europepmc   +1 more source

Comparison of pharmacodynamics and pharmacokinetics of ultra-rapid-acting insulin aspart and rapid-acting insulin aspart around continuous moderate intensity exercise in adults with type 1 diabetes: A randomised controlled trial. [PDF]

Diabetes Obes Metab
Pitt JP, Müller A, Nicholas C, McCarthy OM, Moser O, Bain SC, Sourij H, Bracken RM.   +7 more
europepmc   +1 more source

Effects of dietary intervention combined with insulin aspart on serum nesfatin-1 and CTRP12 levels and pregnancy outcomes in pregnant women with gestational diabetes mellitus. [PDF]

Medicine (Baltimore), 2023
Yang N, Guo R, Guo Y, Wei Y, An N.
europepmc   +1 more source

Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Aspart (MYL-1601D) Compared with Originator Insulin Aspart (Novolog^®) in Patients with Type 1 Diabetes After 24 Weeks: A Randomized Open-Label Study. [PDF]

BioDrugs, 2022
Blevins TC, Raiter Y, Sun B, Donnelly C, Shapiro R, Chullikana A, Rao A, Vashishta L, Ranganna G, Barve A.   +9 more
europepmc   +1 more source

Efficacy and safety of insulin degludec/insulin aspart biosimilar B01711 vs originator insulin degludec/insulin aspart in Chinese patients with type 2 diabetes inadequately controlled on basal or premixed insulin: A multicenter, randomized, open-label, phase 3 study. [PDF]

J Diabetes Investig
Gao L, Cheng Z, Ma G, Cai X, Wang X, Lu Y, Li Z, Li W, Zhao S, Li X, Song C, Gao Y, Geng J, Cao H, Sun J, Ji L.   +15 more
europepmc   +1 more source

Retracted: Insulin Aspart Combined with Exercise Therapy in Spleen Deficiency Type Gestational Diabetes Mellitus: The Effect on Disease Control and Pregnancy Outcomes. [PDF]

Evid Based Complement Alternat Med, 2023
And Alternative Medicine EC.
europepmc   +1 more source

Physical compatibility of insulin aspart, lidocaine, alprostadil and vancomycin with individualised two-in-one parenteral nutrition used in the neonatal intensive care unit. [PDF]

Eur J Hosp Pharm
Van Gelder TG, Vergoossen D, Zonnenberg IA, Lalmohamed A, Koole-Oostveen MI, van Reij EML, van Loon A, Egberts TCG.   +7 more
europepmc   +1 more source